Emcure Pharmaceuticals Ltd. - Research Center
544210 EMCURE Group (B) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 180.85 | 180.85 | 180.85 | 180.85 | 180.85 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 1,661.02 | 1,531.68 | 2,120.92 | 1,733.70 | 1,596.66 |
| Loan funds | |||||
| Secured loans | 1,667.76 | 1,573.79 | 1,305.57 | 1,014.80 | 985.66 |
| Unsecured loans | - | - | - | - | - |
| Total | 3,509.63 | 3,286.32 | 3,607.34 | 2,929.35 | 2,763.17 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 2,317.73 | 2,054.78 | 1,903.54 | 1,673.27 | 1,489.98 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 885.03 | 747.42 | 625.64 | 507.21 | 390.05 |
| Net block | 1,432.71 | 1,307.36 | 1,277.90 | 1,166.06 | 1,099.92 |
| Capital work-in-progress | 253.10 | 239.25 | 192.09 | 326.06 | 405.96 |
| Investments | 690.02 | 563.36 | 863.73 | 407.71 | 310.57 |
| Net current assets | |||||
| Current assets, loans & advances | 2,240.03 | 2,213.21 | 2,529.47 | 1,971.38 | 1,761.12 |
| Less : current liabilities & provisions | 1,106.22 | 1,036.86 | 1,255.86 | 941.85 | 814.40 |
| Total net current assets | 1,133.81 | 1,176.35 | 1,273.62 | 1,029.53 | 946.72 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 3,509.63 | 3,286.32 | 3,607.34 | 2,929.35 | 2,763.17 |
| Notes: | |||||
| Book value of unquoted investments | 690.02 | 563.36 | 863.73 | 407.71 | 310.57 |
| Market value of quoted investments | - | - | - | - | - |
| Contingent liabilities | 66.56 | 89.11 | 45.52 | 52.35 | - |
| Number of equity sharesoutstanding (Lacs) | 1808.52 | 1808.52 | 1808.52 | 1808.52 | 1808.52 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis